Evidence map›Paper›PMID 42482660›Full record

ArticleAnnals of medicine2026

Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.

Jingrui Sui, Lijie Yan, Zengyan Liu, Peiqi Zhao, Xia Zhao, Zhihe Liu, Xiaofeng Luo, Jingjing Ye, Lijie Xing, Yuezhu Zhang and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingrui SuiHematology Department, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Lijie YanHematology Department, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Zengyan LiuHematology Department, Binzhou Medical University Hospital, Binzhou, China.
Peiqi ZhaoLymphoma Department, Tianjin Medical University Cancer Institute, Tianjin, China.
Xia ZhaoLymphoma Department, Affiliated Hospital of Qingdao University, Qingdao, China.
Zhihe LiuLymphoma Department, Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaofeng LuoHematology Department, Fujian Medical University Union Hospital, Fujian, China.
Jingjing YeHematology Department, Qilu Hospital of Shandong University, Jinan, China.
Lijie XingLymphoma Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yuezhu ZhangHematology Department, Binzhou Medical University Hospital, Binzhou, China.
Junqing XuHematology Department, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD5-positive diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype with poor outcomes. Following the approval of Pola-R-CHP in China, this study aimed to evaluate its efficacy as initial therapy for this high-risk population.

methodsWe conducted a multicenter, retrospective study of previously untreated CD5-positive DLBCL patients who received Pola-R-CHP as first-line therapy between April 2023 and February 2025. Treatment response was assessed by PET/CT after 3 cycles and at the end of treatment.

resultsAmong 32 enrolled patients (median age 63.5 years), 78.1% had stage III-IV disease and 59.4% had an International Prognostic Index score ≥3. The overall response rate (ORR) was 100% after 3 cycles, with a complete response rate (CRR) of 71.9%. At end of treatment, the ORR and CRR were 93.8% and 75%, respectively. After a median follow-up of 17.9 months, 2-year progression-free survival (PFS) and overall survival rates (OS) were 70% and 82.7%. After adjusting covariates, failure to achieve a complete response (CR) after 3 cycles was a predictor of inferior survival [PFS HR: 18.1,

conclusionsCD5-positive DLBCL patients exhibited rapid and promising responses to first-line Pola-R-CHP with an acceptable safety profile. Interim response assessment is a potential prognostic factor. In instances where CR is not attained by the interim PET/CT, it is advisable to consider treatment modification, as this may indicate a potential failure to achieve CR.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCD5 AntigensLymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyAdultAgedChinaCyclophosphamideFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesCD5 AntigensCyclophosphamideRituximabCD5-positive DLBCLearly therapeutic adjustmentinterim partial responsePola-R-CHPprogression-free survival

Identifiers

PMID42482660
PMCPMC13393052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.